期刊文献+
共找到2篇文章
< 1 >
每页显示 20 50 100
苦参素联合复方丹参注射液治疗乙型肝炎活动性肝硬化的研究 被引量:12
1
作者 原皓 焦建新 +2 位作者 吴克香 张红梅 孙良华 《疑难病杂志》 CAS 2003年第4期210-212,共3页
目的 探讨苦参素联合复方丹参注射液对乙型肝炎活动性肝硬化的治疗效果。方法将42例乙型肝炎活动性肝硬化患者随机分为观察组和对照组。在常规治疗的基础上,观察组另给予苦参素400 mg肌注,复方丹参注射液14ml入液静脉滴注,每天1次;对照... 目的 探讨苦参素联合复方丹参注射液对乙型肝炎活动性肝硬化的治疗效果。方法将42例乙型肝炎活动性肝硬化患者随机分为观察组和对照组。在常规治疗的基础上,观察组另给予苦参素400 mg肌注,复方丹参注射液14ml入液静脉滴注,每天1次;对照组采用常规治疗。然后观察肝功能、乙肝病毒标记物、肝纤维化指标的变化。结果 疗程结束及治疗结束5个月后,观察组肝功能指标ALT、AST、ALB、A/G、TBIL均较治疗前有显著改善(P<0.05或P<0.01);对照组仅ALT、AST有改善(P<0.05);HBV-DNA及HBeAg阴转率,观察组显著高于对照组(P<0.05);肝纤维化指标水平,观察组治疗后较治疗前显著下降(P<0.05),而且也显著低于对照组治疗后(P<0.05)。观察组少数患者出现腹泻和注射部位硬结。结论 苦参素联合复方丹参注射液能明显控制活动性肝硬化的炎症活动,抑制HBV复制,且具有抗纤维化的作用,无严重不良反应。 展开更多
关键词 苦参素 复方丹参注射液 乙型肝炎 动性肝硬化 治疗 肝纤维化
下载PDF
Pediatric nonalcoholic fatty liver disease,metabolic syndrome and cardiovascular risk 被引量:24
2
作者 Lucia Pacifico Valerio Nobili +2 位作者 Caterina Anania Paola Verdecchia Claudio Chiesa 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第26期3082-3091,共10页
Nonalcoholic fatty liver disease(NAFLD) encompasses a range of liver histology severity and outcomes in the absence of chronic alcohol use.The mildest form is simple steatosis in which triglycerides accumulate within ... Nonalcoholic fatty liver disease(NAFLD) encompasses a range of liver histology severity and outcomes in the absence of chronic alcohol use.The mildest form is simple steatosis in which triglycerides accumulate within hepatocytes.A more advanced form of NAFLD,nonalcoholic steatohepatitis,includes inflammation and liver cell injury,progressive to cryptogenic cirrhosis.NAFLD has become the most common cause of chronic liver disease in children and adolescents.The recent rise in the prevalence rates of overweight and obesity likely explains the NAFLD epidemic worldwide.NAFLD is strongly associated with abdominal obesity,type 2 diabetes,and dyslipidemia,and most patients have evidence of insulin resistance.Thus,NAFLD shares many features of the metabolic syndrome(MetS),a highly atherogenic condition,and this has stimulated interest in the possible role of NAFLD in the development of atherosclerosis.Accumulating evidence suggests thatNAFLD is associated with a significantly greater overall mortality than in the general population,as well as with increased prevalence of cardiovascular disease(CVD),independently of classical atherosclerotic risk factors.Yet,several studies including the pediatric population have reported independent associations between NAFLD and impaired flow-mediated vasodilatation and increased carotid artery intimal medial thickness-two reliable markers of subclinical atherosclerosis-after adjusting for cardiovascular risk factors and MetS.Therefore,the rising prevalence of obesity-related MetS and NAFLD in childhood may lead to a parallel increase in adverse cardiovascular outcomes.In children,the cardiovascular system remains plastic and damage-reversible if early and appropriate interventions are established effectively.Therapeutic goals for NAFLD should address nutrition,physical activity,and avoidance of smoking to prevent not only end-stage liver disease but also CVD. 展开更多
关键词 Nonalcoholic fatty liver disease Metabolicsyndrome Cardiovascular risk CHILDREN
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部